BioSpace News Archive

As organizations working to advance cardiovascular health and the interests of medically underserved communities, the Foundation of the National Lipid Association and the National Medical Association are launching the Take Health to Heart initiative to reverse this alarming trend.

ZyVersa Therapeutics, Inc. announced today that Stephen C. Glover, Co-Founder, Chairman, Chief Executive Officer, and President will present in person at the BIO CEO & Investor Conference being held February 6-7, 2023 at the Marriot Marquis in New York City.

GATC Health today announced that the FDA Modernization Act 2.0 signed into law in December 2022, ends an FDA mandate that experimental drugs must be tested on animals before they are used on humans in clinical trials.

With effect from 20.01.2023, CO.DON’s business activities will be continued in the legal form of a GmbH following a transferring reorganisation.

Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”) today announced that it has entered into definitive agreements for the issuance and sale of 6,744,187 of its shares of common stock (or common stock equivalents) at a purchase price of $0.86 per share (or common stock equivalent) in a registered direct offering.

Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of refractive and retinal eye disorders, today announced topline efficacy and safety results from its ZETA-1 Phase 2 trial evaluating oral APX3330 for the treatment of diabetic retinopathy (DR).

Magenta Therapeutics (Nasdaq: MGTA) today announced that the latest participant dosed at the Cohort 3 level (0.08 mg/kg) in the ongoing MGTA-117 Phase 1/2 Dose-Escalation Clinical Trial in relapsed/refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) experienced a Grade 5 Serious Adverse Event (SAE) (respiratory failure and cardiac arrest resulting in death) deemed to be possibly related to MGTA-117.

Precision Neuroscience Corporation, the only brain–computer interface company developing implants that are designed to be high-resolution, minimally invasive, and reversible, announced a $41 million Series B funding round led by Forepont Capital Partners.

Mersana Therapeutics, Inc. (NASDAQ: MRSN), a clinical-stage biopharmaceutical company focused on discovering and developing a pipeline of antibody-drug conjugates (ADCs) targeting cancers in areas of high unmet medical need, today announced the initiation of patient dosing in its Phase 1 clinical trial of XMT-2056, the company’s lead Immunosynthen product candidate.

Eloxx Pharmaceuticals, Inc. (NASDAQ: ELOX), a leader in ribosomal RNA-targeted genetic therapies for rare diseases, today announced that the first patients have now been enrolled in its Phase 2 study of ELX-02 for the treatment of Alport syndrome in patients with nonsense mutations.